BioCurie
BioCurie is a Wilmington, Delaware-based TechBio company developing ENGINE, an AI-powered platform that uses computational modeling and machine learning to optimize gene and cell therapy manufacturing for pharmaceutical and biotech manufacturers.
- Company typePrivate
- Founded2021
- HeadquartersWilmington, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What BioCurie does
BioCurie is a Wilmington, Delaware-based TechBio company building an artificial-intelligence software platform called ENGINE (ENabling Genomic Engineering) that targets cell and gene therapy manufacturing. The platform combines computational modeling with machine learning to replace traditional trial-and-error process development, addressing manufacturing bottlenecks that limit scalability and patient access to disease-modifying gene therapies — specifically high development costs, variable yields, and lengthy optimization cycles. The company's initial commercial focus is adeno-associated virus (AAV) gene therapy production, with a planned commercial release in late 2026.
The platform is being developed and validated through a consortium assembled in March 2026 that pairs BioCurie with Caring Cross (a nonprofit focused on cell and gene therapy access), St. Jude Children's Research Hospital (clinical and pediatric gene therapy expertise), Center for Breakthrough Medicines / SK pharmteco Cell & Gene US (commercial CDMO perspective), and University City Science Center (regional innovation-ecosystem support). The company's primary disclosed capital event is an up to $9.3 million award from the ARPA-H Health Science Futures Office, announced in February 2026, to fund ENGINE development.
BioCurie's go-to-market is B2B enterprise, targeting pharmaceutical and biotech manufacturers developing gene therapies through direct enterprise sales. Expected revenue mechanics are platform licensing/subscription to manufacturers supplemented by technology services delivered through consortium engagements. The company is pre-commercial, with 1–10 employees and no disclosed paying customers, pricing, or contract values at this stage.
BioCurie firmographics
Firmographics- Name
- BioCurie
- Legal name
- BioCurie
- Website
- https://biocurie.ai
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- BioCurie is a Wilmington, Delaware-based TechBio company developing ENGINE, an AI-powered platform that uses computational modeling and machine learning to optimize gene and cell therapy manufacturing for pharmaceutical and biotech manufacturers.
- Ownership category
- akta.pro rank
BioCurie industry classification
Industry- Product category
- AI Biomanufacturing Software
- NAICS
- Software Publishers (5132)
- SIC
- Services-Prepackaged Software (7372), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industry
- Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)
Keywords
Where BioCurie is headquartered
LocationHeadquarters
- HQ city
- Wilmington
- HQ country
- United States
- HQ region
- North America
Markets served
BioCurie business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Platform Licensing/Subscription: BioCurie is developing an AI-powered digital platform for scalable gene therapy manufacturing with planned commercial release for adeno-associated virus gene therapy production in late 2026. Revenue is expected to be generated through platform licensing to gene therapy manufacturers.
- Technology Services: The company provides technology services to address manufacturing bottlenecks and aims to create a foundation for broader industry deployment through consortium partnerships.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
BioCurie product offering
Product offeringCore offering
BioCurie is developing ENGINE, an AI-powered digital platform that combines computational modeling with machine learning to optimize gene therapy manufacturing processes. The platform replaces trial-and-error process development with in-silico modeling, targeting adeno-associated virus (AAV) gene therapy production. Planned commercial release is late 2026.
Product overview
BioCurie offers a single unified AI-powered digital platform called ENGINE (ENabling Genomic Engineering), designed to optimize gene therapy manufacturing processes. The platform combines computational modeling and machine learning to replace traditional trial-and-error process development, aiming to address manufacturing bottlenecks including high development costs, variable yields, and lengthy optimization cycles that limit scalability and patient access to gene therapies.
Differentiator
Problem solved
Functional benefit
Products and services
- ENGINE AI-powered digital platform that replaces trial-and-error process development with computational modeling and simulation for scalable gene therapy manufacturing. Combines machine learning and advanced modeling to reduce development timelines, manufacturing costs, and production bottlenecks for adeno-associated virus gene therapies.
Quantifiable outcome
- Reduce development timelines for gene therapy manufacturing
- +3 more outcomes
Companies that use BioCurie
Customer profileSegments2 records
Ideal customer profiles1 record
BioCurie technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature3 records
BioCurie partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and supporting.
- Caring CrosscoreCaring Cross is part of the ARPA-H funded consortium to validate and develop the ENGINE platform. As a nonprofit focused on advancing cell and gene therapy access, Caring Cross provides clinical and implementation expertise to ensure the platform addresses real-world manufacturing needs.
- St. Jude Children's Research HospitalcoreSt. Jude Children's Research Hospital is a consortium partner providing research validation for the AI-powered gene therapy manufacturing platform. The partnership brings clinical research expertise and real-world pediatric gene therapy development needs to inform platform development.
- Center for Breakthrough Medicines (SK pharmteco Cell & Gene US)coreCenter for Breakthrough Medicines serves as an industry validation partner representing commercial manufacturing perspective. Their involvement ensures the platform addresses real manufacturing operations and can scale to commercial production requirements.
- University City Science CentersupportingUniversity City Science Center provides regional innovation ecosystem support and infrastructure for the consortium. They serve as a hub for connecting academic and industry partners in the Philadelphia region.
Scale indicators3 records
Recent moves5 records
Expansion highlights5 records
BioCurie competitors and assessment
Company assessmentBroad incumbents
- Cytiva (Danaher): Global leader in bioprocess equipment, consumables, and digital tools for cell and gene therapy manufacturing. Cytiva offers broad process development and manufacturing platforms and represents the incumbent bundle BioCurie would have to integrate with or compete against.
- Sartorius: Major bioprocess solutions provider with PAT/data analytics and cell & gene therapy manufacturing offerings. Sartorius is investing heavily in digital bioprocess capabilities, making it the most directly comparable incumbent building AI/ML into bioprocess workflows.
- Lonza: One of the world's largest CDMOs with significant cell and gene therapy manufacturing capacity. Lonza's scale and process know-how make it both a potential customer/partner and a long-term competitive threat if it internalizes AI optimization.
- Thermo Fisher Scientific: Provides bioprocess production services, analytics, and CDMO capabilities across cell and gene therapy. Its scale and ability to bundle manufacturing services with software make it a key potential competitor for process optimization offerings.
Emerging players
- Ginkgo Bioworks: Synthetic biology and AI-driven bioengineering platform expanding into cell engineering and bioprocess services. Ginkgo represents an adjacent TechBio model applying AI/automation to engineered biology, though its primary focus is organism engineering rather than gene therapy manufacturing.
Direct peers
- Vineti: Specialized software platform for cell and gene therapy orchestration, including manufacturing and supply chain workflows. Vineti targets the same buyer (gene therapy developers/CDMOs) with a complementary, software-only value proposition.
- Benchling: Cloud-based software platform for life sciences R&D and bioprocess development. Benchling serves biotech and gene therapy developers with informatics for process records, samples, and analytical data — a comparable software-first approach in the same buyer workflow.
- Dotmatics: Scientific informatics platform spanning lab data, bioprocess, and analytics. Dotmatics overlaps with BioCurie's intent to bring digital tools into gene therapy process development and manufacturing workflows.
- TetraScience: Cloud-native data platform for biopharma R&D and manufacturing, focused on harmonizing instrument and process data for AI/ML use cases. Directly comparable as a software layer enabling AI-driven bioprocess insight.
- DataHow: Specialist in data-driven modeling and AI for bioprocess development, particularly for cell culture and biologics. DataHow is one of the closest pure-play comparables for AI/ML-driven bioprocess process optimization.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights5 records
Customer concentration
BioCurie financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioCurie leadership team
Management profileNumber of profiles
Profiles1 record
BioCurie funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioCurie M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioCurie
What does BioCurie do?
BioCurie is developing ENGINE, an AI-powered digital platform that combines computational modeling with machine learning to optimize gene therapy manufacturing processes. The platform replaces trial-and-error process development with in-silico modeling, targeting adeno-associated virus (AAV) gene therapy production. Planned commercial release is late 2026.
Is BioCurie a public or private company?
BioCurie is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was BioCurie founded?
BioCurie was founded in 2021. It employs 1 to 10 people.
Where is BioCurie based?
BioCurie is headquartered in Wilmington, United States, in the North America region.
How does BioCurie make money?
Two revenue lines are on record. Platform Licensing/Subscription is the primary driver. The others are technology Services.
Who are BioCurie's main competitors?
Broad incumbents on record are Cytiva (Danaher), Sartorius, Lonza and Thermo Fisher Scientific. Ginkgo Bioworks is listed as an emerging player. Direct peers are Vineti, Benchling, Dotmatics, TetraScience and DataHow.
Does BioCurie have an API?
No public API is recorded for BioCurie.
What industry is BioCurie in?
BioCurie's product category is AI Biomanufacturing Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAJAD, Bioinformatics & Multi-omics Analysis Software. Its NAICS code is 5132 and its SIC code is 7372.